Tyme Technologies (TYME) Announces Board Changes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St set to open higher as tech rebounds, Micron earnings eyed
- Brent hits lowest since before start of Iran war on expectations of smoother oil flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
TYME Technologies, Inc. Announces Changes to its Board of Directors
March 25, 2022 8:00 AM EDTIndustry veteran, Christine D. Baker, joins Board of Directors
Douglas A. Michels appointed Chairman of the Board
BEDMINSTER, N.J.--(BUSINESS WIRE)-- TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), today announced changes to its Board of Directors.
Christine D. Baker Named to Board of Directors
The Company is pleased to announce that Christine D. Baker has been appointed to TYMEs Board of Directors. Ms. Baker brings over 30 years of experience in the biotech/pharmaceutical industry, with expertise in... More
